Blood · 2014 · 85 citations · 26 references
MedicineOncologyPharmacotherapyChemotherapyHematologic OncologyImmuno-oncology PharmacotherapyCancer ImmunotherapyChemotherapy In Hematologic MalignanciesCytotoxic ChemotherapyHematologic Malignancy PharmacotherapyHematologic Malignancy TherapyLymphoid TumorsChemotherapy Administration In LymphomaClinical Trial Efficacy EvaluationHodgkin Lymphoma TherapyHodgkin Lymphoma TreatmentLymphoma ChemotherapyRandomized Clinical TrialsRelapsed Disease TherapyRituximab-based Therapy
Brentuximab vedotin is an anti-CD30 antibody-drug conjugate with proven efficacy in patients with CD30(+) malignancies, including classical Hodgkin lymphoma and anaplastic large cell lymphoma. Promising activity has also been seen in other lymphomas that express CD30. Because of its acceptable toxicity profile and significant clinical efficacy, single-agent brentuximab vedotin is an approved treatment for relapsed patients with these diseases. Brentuximab vedotin has safely been combined with chemotherapy and is now being compared with standard treatments in randomized trials.
26
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Anas Younes, Nancy L. Bartlett, John P. Leonard et al. · New England Journal of Medicine · 2010 · 1.4K citations · Full text
Medicine, Oncology, Pharmacology +17
Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Nicole M. Okeley, Jamie B. Miyamoto, Xinqun Zhang et al. · Clinical Cancer Research · 2010 · 387 citations · Full text
Pharmacy, Oncology, Pharmacology +17